TY - JOUR
T1 - A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever
AU - Van Metre, Thomas E.
AU - Adkinson, N. Franklin
AU - Amodio, Frank J.
AU - Kagey-Sobotka, Anne
AU - Lichtenstein, Lawrence M.
AU - Mardiney, Michael R.
AU - Norman, Philip S.
AU - Rosenberg, Gary L.
N1 - Funding Information:
From the Division of Clinical Immuwlogy, Department of Medicine, The Johns Hopkins University School of Medicine, and the Allergy Clinic of The Johns Hopkins Hospital. Supported in part by National Institutes of Health grants AI 11936-05 and 3 P50 AL 10304-0851 ACIRC, and Outpatient Department and Clinical Research Center grant 5 M 01 RR 00722-07. Computational assistance was received from CLINFO, sponsored by National Institutes of Health grant 5MOIRR35-20. Received for publication July 15, 198 I Accepted for publication Oct. 13, 198 1. Reprint requests to: Thomas E. Van Metre, Jr., M.D., 11 East Chase St., Baltimore, MD 21202.
PY - 1982/2
Y1 - 1982/2
N2 - In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) and with placebo (11 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p < 0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo group and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.
AB - In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) and with placebo (11 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p < 0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo group and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.
UR - http://www.scopus.com/inward/record.url?scp=0020059768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020059768&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(82)90098-7
DO - 10.1016/0091-6749(82)90098-7
M3 - Article
C2 - 7056949
AN - SCOPUS:0020059768
SN - 0091-6749
VL - 69
SP - 181
EP - 193
JO - The Journal of allergy and clinical immunology
JF - The Journal of allergy and clinical immunology
IS - 2
ER -